TOKYO, Dec 2, 2025 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code: E2814) was presented at ...

Cognito Therapeutics Announces Presentation of New CSF Proteomic and EEG Biomarker Data for Spectris™ in Alzheimer’s Disease at CTAD 2025 Cognito Therapeutics, a clinical-stage medical device company ...

Global prevalence estimates show Alzheimer’s disease accounts for most dementia, with ~57 million people affected in 2021 and numbers projected to triple by 2050. People and health systems face rising ...

TORONTO — An expert panel convened by the Alzheimer’s Association has released the first clinical guidelines to help clinicians choose the most appropriate blood-based biomarker (BBM) test to aid in ...

OTTAWA, Ontario — Looking for Alzheimer’s disease (AD) biomarkers in plasma instead of cerebrospinal fluid (CSF) is a simpler form of screening individuals for AD pathology and could result in earlier ...